Cerebrospinal fluid neurofilament concentration reflects disease severity in frontotemporal degeneration

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Annals of Neurology

• Publication date

  2014-01-01

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1002/ana.24052PMID 24242746PMCID PMC4020786
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The California verbal learning test

  2016cited by this paper
• Cerebrospinal fluid neurofilament light chain protein levels in subtypes of frontotemporal dementia

  2013influential reference
• The advantages of frontotemporal degeneration drug development (part 2 of frontotemporal degeneration: The next therapeutic frontier)

  2013influential reference
• Neuroimaging signatures of frontotemporal dementia genetics: C9ORF72, tau, progranulin and sporadics

  2012cited by this paper
• Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease.

  2012influential reference
• Elevated cerebrospinal fluid neurofilament light levels in patients with amyotrophic lateral sclerosis: a possible marker of disease severity and progression

  2012cited by this paper
• Clinical diagnosis of Alzheimer's disease: Report of the NINCDS—ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

  2011cited by this paper
• Classification of primary progressive aphasia and its variants

  2011cited by this paper
• Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS.

  2011cited by this paper
• Clinicopathological correlations in corticobasal degeneration

  2011cited by this paper
• Amyloid vs FDG-PET in the differential diagnosis of AD and FTLD

  2011cited by this paper
• Alzheimer's disease: progress in prediction

  2010cited by this paper
• Neurofilament light as a prognostic marker in multiple sclerosis

  2010cited by this paper
• Clinical, neuroimaging and neuropathological features of a new chromosome 9p-linked FTD-ALS family

  2010cited by this paper
• CSF biomarkers in frontotemporal lobar degeneration with known pathology

  2008influential reference
• Frontal paralimbic network atrophy in very mild behavioral variant frontotemporal dementia.

  2008influential reference
• CSF Neurofilaments in Frontotemporal Dementia Compared with Early Onset Alzheimer’s Disease and Controls

  2007influential reference
• CSF neurofilament light chain and tau differentiate multiple system atrophy from Parkinson's disease.

  2007cited by this paper
• Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17

  2006cited by this paper
• The pathological basis of semantic dementia.

  2005cited by this paper
• Clinical characteristics in early Parkinson's disease in a central California population‐based study

  2005cited by this paper
• Voxel-based morphometry of the human brain: Methods and applications

  2005cited by this paper
• Neurofilament phosphoforms: surrogate markers for axonal injury, degeneration and loss.

  2005influential reference
• Role of Integrated 18-F FDG PET/CT in Recurrent Ovarian Cancer

  2005cited by this paper
• Amyloid beta(1-42) and phosphorylated tau in CSF as markers for early-onset Alzheimer disease.

  2004cited by this paper
• Amyloid β(1–42) and phosphorylated tau in CSF as markers for early-onset Alzheimer disease

  2004cited by this paper
• Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease.

  2003cited by this paper
• Elevated neurofilament levels in neurological diseases.

  2003cited by this paper
• Tau and A&bgr;42 protein in CSF of patients with frontotemporal degeneration

  2002cited by this paper
• Boston Naming Test

  2001cited by this paper
• Cytoskeleton proteins in CSF distinguish frontotemporal dementia from AD

  2000cited by this paper
• Tau protein in cerebrospinal fluid from semantic dementia patients.

  2000cited by this paper
• CSF levels of tau, β-amyloid1–42 and GAP-43 in frontotemporal dementia, other types of dementia and normal aging

  2000cited by this paper
• Alzheimer's Disease and Its Focal Variants

  2000cited by this paper
• Neurofilament protein levels in CSF are increased in dementia

  1999cited by this paper
• Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria.

  1999cited by this paper
• Increased tau in the cerebrospinal fluid of patients with frontotemporal dementia and Alzheimer's disease.

  1999cited by this paper
• A structural scaffolding of intermediate filaments in health and disease.

  1998cited by this paper
• Neurofilament protein in cerebrospinal fluid: a potential marker of activity in multiple sclerosis

  1998cited by this paper
• Frontotemporal lobar degeneration

  1998cited by this paper
• Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17

  1998cited by this paper
• Patients with Amyotrophic Lateral Sclerosis and Other Neurodegenerative Diseases Have Increased Levels of Neurofilament Protein in CSF

  1996influential reference
• Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome)

  1996cited by this paper
• Controlling the false discovery rate: a practical and powerful approach to multiple testing

  1995cited by this paper
• The Clinical Dementia Rating (CDR)

  1993cited by this paper
• Clinical diagnosis of Alzheimer's disease

  1984cited by this paper
• “Mini-mental state”: A practical method for grading the cognitive state of patients for the clinician

  1975cited by this paper

• Label-free plasmonic biosensors for neurodegenerative disease diagnosis: Progress and perspectives

  2026cites this paper
• Distinct plasma inflammatory signatures reflect disease severity and progression in progressive supranuclear palsy: a prospective cohort study.

  2025cites this paper
• Distinctive autophagy/mitophagy biomarker profiles in frontotemporal lobar degeneration and Alzheimer’s disease

  2025cites this paper
• Differentiating Progressive Supranuclear Palsy and Corticobasal Syndrome: Insights from Cerebrospinal Fluid Biomarkers—A Narrative Review

  2025cites this paper
• Diagnostic value of fluid‐based non‐amyloid biomarkers for Alzheimer's disease and related dementias in a clinic‐based cohort from South Asia

  2025cites this paper
• Clinical use and reporting of neurofilament quantification in neurological disorders: A global overview

  2025cites this paper
• Elevated Cerebrospinal Fluid Ubiquitin Carboxyl‐Terminal Hydrolase Isozyme L1 in Asymptomatic C9orf72 Hexanucleotide Repeat Expansion Carriers

  2024cites this paper
• The pursuit for markers of disease progression in behavioral variant frontotemporal dementia: a scoping review to optimize outcome measures for clinical trials

  2024cites this paper
• Neurofilaments and progranulin are related to atrophy in frontotemporal lobar degeneration – A transdiagnostic study cross‐validating atrophy and fluid biomarkers

  2024cites this paper
• Cerebrospinal fluid and blood neurofilament light chain levels in amyotrophic lateral sclerosis and frontotemporal degeneration: A meta‐analysis

  2024cites this paper
• Increased CXCL12, a potential CSF biomarker for differential diagnosis of amyotrophic lateral sclerosis

  2024cites this paper
• The Impact of Cognitive Behavioral Therapy for Insomnia on Neurofilament Light and Phosphorylated Tau in Individuals with a Concussion

  2024cites this paper
• A Critical Appraisal of Blood-Based Biomarkers for Alzheimer's Disease.

  2024cites this paper
• CSF Proteomics in Patients With Progressive Supranuclear Palsy

  2024cites this paper
• Neurofilaments in neurologic disease.

  2024cites this paper
• Pumping up the Fight against Multiple Sclerosis: The Effects of High-Intensity Resistance Training on Functional Capacity, Muscle Mass, and Axonal Damage

  2024cites this paper
• Induced pluripotent stem cell models as a tool to investigate and test fluid biomarkers in Alzheimer's disease and frontotemporal dementia

  2024cites this paper
• Temporal serum neurofilament light chain concentrations in sheep inoculated with the agent of classical scrapie

  2024cites this paper
• Mapping neurodegeneration across the Huntington's disease spectrum: a five-year longitudinal analysis of plasma neurofilament light

  2024cites this paper
• Alzheimer’s Disease-Related Cerebrospinal Fluid Biomarkers in Progressive Supranuclear Palsy

  2024cites this paper
• Neurofilaments Light Chain in Neurodegenerative Dementias: A Review of Imaging Correlates

  2024cites this paper
• Serum neurofilament light chain as a prognostic marker of all-cause mortality in a national sample of US adults

  2024cites this paper
• Pharmacotherapies for the Treatment of Progressive Supranuclear Palsy: A Narrative Review

  2024cites this paper
• Neuropsychological impairment in amyotrophic lateral sclerosis–frontotemporal spectrum disorder

  2023cites this paper
• Cortical thickness modeling and variability in Alzheimer’s disease and frontotemporal dementia

  2023cites this paper
• Frontotemporal Dementia, Where Do We Stand? A Narrative Review

  2023cites this paper
• Serum neurofilament light chain - A potential biomarker for polyneuropathy in type 2 diabetes?

  2023cites this paper
• Plasma Neurofilament Light Chain Predicts Mortality and Long-Term Neurological Outcomes in Patients with Intracerebral Hemorrhage

  2023cites this paper
• Plasma neurofilament light and brain volumetric outcomes among middle‐aged urban adults

  2023cites this paper
• Frontotemporal lobar degeneration

  2023cites this paper
• Cerebrospinal fluid neurofilament light chain and total-tau as biomarkers of neurodegeneration in Alzheimer's disease and frontotemporal dementia.

  2023cites this paper
• Plasma Biomarkers and Positron Emission Tomography Tau Pathology in Progressive Supranuclear Palsy

  2023cites this paper
• Biomarker discovery in progressive supranuclear palsy from human cerebrospinal fluid

  2023influential citation
• Discovery of Biomarkers for Amyotrophic Lateral Sclerosis from Human Cerebrospinal Fluid Using Mass-Spectrometry-Based Proteomics

  2023cites this paper
• Unexpected gender differences in progressive supranuclear palsy reveal efficacy for davunetide in women

  2023cites this paper
• Associations between cerebrospinal fluid markers and cognition in ageing and dementia: A systematic review

  2022cites this paper
• Plasma NfL is associated with mild cognitive decline in patients with diabetes

  2022cites this paper
• New developments of biofluid‐based biomarkers for routine diagnosis and disease trajectories in frontotemporal dementia

  2022cites this paper
• Prognostic value of serum/plasma neurofilament light chain for COVID‐19‐associated mortality

  2022influential citation
• Exploring Neurofilament Light Chain and Exosomes in the Genetic Forms of Frontotemporal Dementia

  2022cites this paper
• Neurofilament Light Chain Levels in Frontotemporal Dementia and Progressive Supranuclear Palsy: A Systematic Review

  2022cites this paper
• Plasma and CSF NfL are differentially associated with biomarker evidence of neurodegeneration in a community‐based sample of 70‐year‐olds

  2022cites this paper
• Comprehensive cross-sectional and longitudinal analyses of plasma neurofilament light across FTD spectrum disorders

  2022cites this paper
• Do Patients with Progressive Supranuclear Palsy Have Episodic Memory Impairment? A Systematic Review

  2022cites this paper
• Pathophysiological Underpinnings of Extra-Motor Neurodegeneration in Amyotrophic Lateral Sclerosis: New Insights From Biomarker Studies

  2022cites this paper
• The role of neurofilament light in genetic frontotemporal lobar degeneration

  2022cites this paper
• Plasma neurofilament light as blood marker for poor brain white matter integrity among middle-aged urban adults.

  2022cites this paper
• Prognostic Value of Serum/Plasma Neurofilament Light Chain for COVID-19 Associated Mortality

  2022cites this paper
• Plasma neurofilament light and its association with all-cause mortality risk among urban middle-aged men and women

  2022cites this paper
• Temporal order of clinical and biomarker changes in familial frontotemporal dementia

  2022cites this paper
• Autopsy-diagnosed neurodegenerative dementia cases support the use of cerebrospinal fluid protein biomarkers in the diagnostic work-up

  2021cites this paper
• Serum Neurofilament Light in Patients with Frontotemporal Dementia Caused by CHMP2B Mutation

  2021cites this paper
• Discovery of Biomarkers for Amyotrophic Lateral Sclerosis and Frontotemporal Lobar Degeneration From Human Cerebrospinal Fluid Using Mass Spectrometry-Based Proteomics

  2021cites this paper
• Fluid Biomarkers of Frontotemporal Lobar Degeneration.

  2021cites this paper
• Blood Biomarkers in Frontotemporal Dementia: Review and Meta-Analysis

  2021cites this paper
• A novel orally active HDAC6 inhibitor T-518 shows a therapeutic potential for Alzheimer’s disease and tauopathy in mice

  2021cites this paper
• Plasma Neurofilament Light and Future Declines in Cognition and Function in Alzheimer’s Disease in the FIT-AD Trial

  2021cites this paper
• Preclinical in vivo longitudinal assessment of KG207-M as a disease-modifying Alzheimer’s disease therapeutic

  2021cites this paper
• Cerebrospinal Fluid Biomarkers of Myeloid and Glial Cell Activation Are Correlated With Multiple Sclerosis Lesional Inflammatory Activity

  2021cites this paper
• Body Mass Index and Allostatic Load are Directly Associated with Longitudinal Increase in Plasma Neurofilament Light Among Urban Middle-aged Adults.

  2021cites this paper
• Biosensor approaches on the diagnosis of neurodegenerative diseases: Sensing the past to the future.

  2021cites this paper
• Association of Plasma Neurofilament Light With Small Vessel Disease Burden in Nondemented Elderly: A Longitudinal Study.

  2021cites this paper
• Intermittent hypoxia treatment alleviates memory impairment in the 6-month-old APPswe/PS1dE9 mice and reduces amyloid beta accumulation and inflammation in the brain

  2021cites this paper
• Plasma neurofilament light as a potential biomarker for cognitive decline in a longitudinal study of middle-aged urban adults

  2021cites this paper
• Effect of the Histone Deacetylase Inhibitor FRM-0334 on Progranulin Levels in Patients With Progranulin Gene Haploinsufficiency

  2021cites this paper
• A data-driven disease progression model of fluid biomarkers in genetic frontotemporal dementia

  2021cites this paper
• Serum neurofilament light chain as a surrogate of cognitive decline in sporadic and familial frontotemporal dementia

  2021cites this paper
• The fluid biomarkers of Alzheimer’s disease

  2021cites this paper
• Behavioral Variant Frontotemporal Dementia

  2021cites this paper
• Neurofilament Light Chain as Biomarker for Amyotrophic Lateral Sclerosis and Frontotemporal Dementia

  2021cites this paper
• Systematic Review: Genetic, Neuroimaging, and Fluids Biomarkers for Frontotemporal Dementia Across Latin America Countries

  2021cites this paper
• Diagnostic and prognostic value of plasma neurofilament light and total-tau in sporadic Creutzfeldt-Jakob disease

  2021cites this paper
• Speech and language impairments in behavioral variant frontotemporal dementia: A systematic review

  2021cites this paper
• Plasma Neurofilament Light for Prediction of Disease Progression in Familial Frontotemporal Lobar Degeneration

  2021cites this paper
• Tracking disease progression in familial and sporadic frontotemporal lobar degeneration: Recent findings from ARTFL and LEFFTDS

  2020cites this paper
• Contribution of CSF biomarkers to early‐onset Alzheimer's disease and frontotemporal dementia neuroimaging signatures

  2020cites this paper
• Plasma glial fibrillary acidic protein is raised in progranulin-associated frontotemporal dementia

  2020cites this paper
• Neurofilament Light Chain Related to Longitudinal Decline in Frontotemporal Lobar Degeneration.

  2020cites this paper
• Use of cerebrospinal fluid in diagnosis of dementia

  2020cites this paper
• Fluid biomarkers in frontotemporal dementia: past, present and future

  2020cites this paper
• Increased Neurofilament Light Chain and YKL-40 CSF Levels in One Japanese IBMPFD Patient With VCP R155C Mutation: A Clinical Case Report With CSF Biomarker Analyses

  2020cites this paper
• Research and progress on biomarkers of neuromyelitis optica spectrum disorders

  2020cites this paper
• ATN incorporating cerebrospinal fluid neurofilament light chain detects frontotemporal lobar degeneration

  2020cites this paper
• NfL and pNfH are increased in Friedreich’s ataxia

  2020cites this paper
• Neurofilament Light Chain as A Biomarker for Brain Metastases

  2020cites this paper
• Frontotemporal dementia: a conference report from the 2nd FinFTD Symposium.

  2020cites this paper
• Amyloid-beta modulates the association between neurofilament light chain and brain atrophy in Alzheimer’s disease

  2020cites this paper
• Serum neurofilament light chain in FTLD: association with C9orf72, clinical phenotype, and prognosis

  2020cites this paper
• Brain delivery and activity of a lysosomal enzyme using a blood-brain barrier transport vehicle in mice

  2020cites this paper
• A pilot study of the utility of cerebrospinal fluid neurofilament light chain in differentiating neurodegenerative from psychiatric disorders: A ‘C-reactive protein’ for psychiatrists and neurologists?

  2020cites this paper
• Diagnostic and prognostic value of serum NfL and p-Tau181 in frontotemporal lobar degeneration

  2020cites this paper
• Plasma neurofilament light protein correlates with diffusion tensor imaging metrics in frontotemporal dementia

  2020influential citation
• The role of neurofilament light chain in frontotemporal dementia: a meta-analysis

  2020cites this paper
• Altered levels of CSF proteins in patients with FTD, presymptomatic mutation carriers and non-carriers

  2020cites this paper
• New directions in clinical trials for frontotemporal lobar degeneration: Methods and outcome measures

  2020cites this paper
• Cerebrospinal fluid neurofilament light concentration predicts brain atrophy and cognition in Alzheimer's disease

  2020cites this paper
• Leveraging preclinical models for the development of Alzheimer disease therapeutics

  2020cites this paper
• Synaptic, axonal damage and inflammatory cerebrospinal fluid biomarkers in neurodegenerative dementias

  2020cites this paper
• Editorial: Back to the Future: On the Road Towards Precision Psychiatry

  2020cites this paper
• Plasma metabolites associated with biomarker evidence of neurodegeneration in cognitively normal older adults

  2020cites this paper